Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
It is of strategic importance to the company to bring additional high-profile institutional investors on board, while our existing key investors continue to support us We are very pleased we achieved this. This is important external validation of the quality of our programs,…
We're approaching an important milestone in our pancreatic cancer program.
Updated overall survival data from our phase 2a clinical trial of CAN-2409 is expected this quarter.
Stay tuned for updates on this program!
$CADL
http://x.com/i/article/1889675027567542272
Just published: the data shows two pathways underpinning the mechanism of action of CAN-2409 action that overcome cell exhaustion and decreases immune suppression. @CandelTx
